These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 29355992)

  • 21. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
    Tangelder MJ; Nwachuku CE; Jaff M; Baumgartner I; Duggal A; Adams G; Ansel G; Grosso M; Mercuri M; Shi M; Minar E; Moll FL
    J Endovasc Ther; 2015 Apr; 22(2):261-8. PubMed ID: 25809373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of aspirin and clopidogrel resistance in peripheral arterial disease.
    Guirgis M; Thompson P; Jansen S
    J Vasc Surg; 2017 Nov; 66(5):1576-1586. PubMed ID: 28893489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.
    Kochar A; Mulder H; Rockhold FW; Baumgartner I; Berger JS; Blomster JI; Fowkes FGR; Katona BG; Lopes RD; Al-Khalidi HR; Mahaffey KW; Norgren L; Hiatt WR; Patel MR; Jones WS
    Circ Cardiovasc Qual Outcomes; 2020 Nov; 13(11):e006550. PubMed ID: 33176462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease.
    Kitrou P; Katsanos K; Karnabatidis D; Reppas L; Brountzos E; Spiliopoulos S
    Curr Vasc Pharmacol; 2017; 15(5):430-445. PubMed ID: 28595535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial.
    Qamar A; Morrow DA; Creager MA; Scirica BM; Olin JW; Beckman JA; Murphy SA; Bonaca MP
    Vasc Med; 2020 Apr; 25(2):124-132. PubMed ID: 32000630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiplatelet therapy in peripheral artery disease.
    Violi F; Basili S; Berger JS; Hiatt WR
    Handb Exp Pharmacol; 2012; (210):547-63. PubMed ID: 22918746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse cardiovascular outcomes in relation to suboptimal antithrombotic therapy use in patients undergoing peripheral artery disease angioplasty: lost opportunities?
    Bodansky DM; Allon IR; Apostolakis S; Lip GY
    Int J Clin Pract; 2015 Feb; 69(2):162-8. PubMed ID: 24898695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombotic Therapy for Peripheral Artery Disease: Recent Advances.
    Hussain MA; Al-Omran M; Creager MA; Anand SS; Verma S; Bhatt DL
    J Am Coll Cardiol; 2018 May; 71(21):2450-2467. PubMed ID: 29793635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of antiplatelet and antithrombotic therapy for secondary prevention of ischemic stroke in patients with peripheral artery disease: population-based follow-up study in Taiwan.
    Lee WH; Chu CY; Hsu PC; Su HM; Lin TH; Voon WC; Lai WT; Sheu SH
    Circ J; 2013; 77(4):1046-52. PubMed ID: 23269006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Harrington RA; Becker RC; Ezekowitz M; Meade TW; O'Connor CM; Vorchheimer DA; Guyatt GH
    Chest; 2004 Sep; 126(3 Suppl):513S-548S. PubMed ID: 15383483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic Literature Review of Randomized Trials Comparing Antithrombotic Therapy Following Revascularization Procedures in Patients With Peripheral Artery Disease.
    Schindewolf M; Beyer-Westendorf J; Balradj J; Bowrin K; Huelsebeck M; Briere JB
    Angiology; 2020 Oct; 71(9):773-790. PubMed ID: 32638610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence.
    Koutsoumpelis A; Argyriou C; Tasopoulou KM; Georgakarakos EI; Georgiadis GS
    Curr Pharm Des; 2018; 24(38):4511-4515. PubMed ID: 30585539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antithrombotic Therapy in Peripheral Artery Disease: Stepping in the Right Direction.
    Hand KR; Hale GM
    Am J Cardiovasc Drugs; 2021 Sep; 21(5):523-534. PubMed ID: 33611741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antithrombotic Therapy in Peripheral Artery Disease: Generating and Translating Evidence Into Practice.
    Jones WS; Patel MR
    J Am Coll Cardiol; 2018 Jan; 71(3):352-362. PubMed ID: 29348028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
    Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
    Capell WH; Bonaca MP; Nehler MR; Chen E; Kittelson JM; Anand SS; Berkowitz SD; Debus ES; Fanelli F; Haskell L; Patel MR; Bauersachs R; Hiatt WR
    Am Heart J; 2018 May; 199():83-91. PubMed ID: 29754671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Sobel M; Verhaeghe R
    Chest; 2008 Jun; 133(6 Suppl):815S-843S. PubMed ID: 18574279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
    Bonaca MP; Bhatt DL; Braunwald E; Cohen M; Steg PG; Storey RF; Held P; Jensen EC; Sabatine MS
    Am Heart J; 2014 Apr; 167(4):437-444.e5. PubMed ID: 24655690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L;
    JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.